Ocular drug delivery nanowafer with enhanced therapeutic efficacy

ACS Nano

Volumn 9, Issue 2, 2015, Pages 1749-1758

  Yuan, Xiaoyong ^a   Marcano, Daniela C ^a   Shin, Crystal S ^a   Hua, Xia ^a   Isenhart, Lucas C ^a   Pflugfelder, Stephen C ^a   Acharya, Ghanashyam ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

corneal neovascularization; drug delivery; inflammation; nanowafer; therapeutic efficacy

Indexed keywords

DROPS; DRUG DELIVERY; DRUG PRODUCTS; FUNCTIONAL POLYMERS; TARGETED DRUG DELIVERY; TISSUE REGENERATION;

CONFOCAL IMAGING; DRUG DELIVERY SYSTEM; INFLAMMATION; NANOWAFER; NEO-VASCULARIZATION; OCULAR DRUG DELIVERY; PATIENT COMPLIANCE; THERAPEUTIC EFFICACY;

CONTROLLED DRUG DELIVERY;

AXITINIB; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; CORNEA; CORNEAL NEOVASCULARIZATION; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG RELEASE; EYE; FEMALE; IMMUNOLOGY; MOUSE; NANOTECHNOLOGY; PROCEDURES; VASCULARIZATION; WOUND HEALING;

ANIMALS; CORNEA; CORNEAL NEOVASCULARIZATION; DIFFUSION; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; EYE; FEMALE; IMIDAZOLES; INDAZOLES; MICE; MICE, INBRED C57BL; NANOTECHNOLOGY; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; WOUND HEALING;

EID: 84923444349     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn506599f     Document Type: Article

References (43)

1. Eye health statistics at a glance. Compiled by American Academy of Ophthalmology. April 2011. http://www.aao.org/newsroom/upload/Eye-Health-Statistics-April-2011.pdf.
2. Azar, D. T. Corneal Angiogenic Privilege: Angiogenic and Antiangiogenic Factors in Corneal Avascularity, Vasculogenesis, and Wound Healing Trans. Am. Ophthalmol. Soc. 2006, 104, 264-302
3. Urtti, A. Challenges and Obstacles of Ocular Pharmacokinetics and Drug Delivery Adv. Drug Delivery Rev. 2006, 58, 1131-1135
4. Novack, G. D. Ophthalmic Drug Delivery: Development and Regulatory Considerations Clin. Pharmacol. Ther. 2009, 85, 539-543
5. Kim, Y. C.; Chiang, B.; Wu, X.; Prausnitz, M. R. Ocular Delivery of Macromolecules J. Controlled Release 2014, 190, 172-181
6. Mannermaa, E.; Vellonen, K.-S.; Urtti, A. Drug Transport in Corneal Epithelium and Blood-Retina Barrier: Emerging Role of Transporters in Ocular Pharmacokinetics Adv. Drug Delivery Rev. 2006, 58, 1136-1163
7. Salminen, L. Review: Systemic Absorption of Topically Applied Ocular Drugs in Humans J. Ocul. Pharmacol. 1990, 6, 243-249
8. Baudouin, C. Side Effects of Antiglaucomatous Drugs on the Ocular Surface Curr. Opin. Ophthalmol. 1996, 7, 80-86
9. Topalkara, A. C.; Guler, C.; Arici, D. S.; Arici, M. K. Adverse Effects of Topical Antiglaucoma Drugs on the Ocular Surface Clin. Exp. Ophthalmol. 2000, 28, 113-117
10. Hoffart, L.; Matonti, F.; Conrath, J.; Daniel, L.; Ridings, B.; Masson, G. S.; Chavane, F. Inhibition of Corneal Neovascularization after Alkali Burn: Comparison of Different Doses of Bevacizumab in Monotherapy or Associated with Dexamethasone Clin. Exp. Ophthalmol. 2010, 38, 346-352
11. Mello, G. R.; Pizzolatti, M. L.; Wasilewski, D.; Santhiago, M. R.; Budel, V.; Moreira, H. The Effect of Subconjunctival Bevacizumab on Corneal Neovascularization, Inflammation and Re-epithelization in a Rabbit Model Clinics 2011, 66, 1443-1449
12. Diebold, Y.; Calonge, M. Applications of Nanoparticles in Ophthalmology Prog. Retina Eye Res. 2010, 29, 596-609
13. Gershkovich, P.; Wasan, K. M.; Barta, C. A. A Review of the Application of Lipid-Based Systems in Systemic, Dermal, Transdermal, and Ocular Drug Delivery Crit. Rev. Ther. Drug 2008, 25, 545-584
14. Choy, Y. B.; Park, J.-H.; McCarey, B. E.; Edelhauser, H. F.; Prausnitz, M. R. Mucoadhesive Microdiscs Engineered for Ophthalmic Drug Delivery: Effect of Particle Geometry and Formulation on Preocular Residence Time Invest. Ophthalmol. Vis. Sci. 2008, 49, 4808-4815
15. Chang, E.; McClellan, A. J.; Farley, W. J.; Li, D.-Q.; Pflugfelder, S. C.; De Paiva, C. Biodegradable PLGA-Based Drug Delivery Systems for Modulating Ocular Surface Disease under Experimental Murine Dry Eye J. Clin. Exp. Ophthalmol. 2011, 2, 191
16. He, C.; Kim, S. W.; Lee, D. S. In Situ Gelling Stimuli-Sensitive Block Copolymer Hydrogels for Drug Delivery J. Controlled Release 2008, 127, 189-207
17. Gulsen, D.; Chauhan, A. Ophthalmic Drug Delivery through Contact Lenses Invest. Ophthalmol. Vis. Sci. 2004, 45, 2342-2347
18. Singh, K.; Nair, A. B.; Kumar, A.; Kumria, R. Novel Approaches in Formulation and Drug Delivery using Contact Lenses J. Basic Clin. Pharm. 2011, 2, 87-101
19. Shin, Y. J.; Hyon, J. Y.; Choi, W. S.; Yi, K.; Chung, E.-S.; Chung, T.-Y.; Wee, W. R. Chemical Injury-Induced Corneal Opacity and Neovascularization Reduced by Rapamycin via TGF-β1/ERK Pathways Regulation Invest. Ophthalmol. Vis. Sci. 2013, 54, 4452-4458
20. Ludwig, A. The Use of Mucoadhesive Polymers in Ocular Drug Delivery Adv. Drug Delivery Rev. 2005, 57, 1595-1639
21. Moshirfar, M.; Pierson, K.; Hanamaikai, K.; Santiago-Caban, L.; Muthappan, V.; Passi, S. F. Artificial Tears Potpourri: A Literature Review Clin. Ophthalmol. 2014, 8, 1419-1433
22. Aragona, P.; Spinella, R.; Rania, L.; Postorino, E.; Sommario, M. S.; Roszkowska, A. M.; Puzzolo, D. Safety and Efficacy of 0.1% Clobetasone butyrate Eyedrops in the Treatment of Dry Eye in Sjögren Syndrome Eur. J. Ophthalmol. 2013, 23, 368-376
23. Acharya, G.; Shin, C. S.; McDermott, M.; Mishra, H.; Park, H.; Kwon, I. C.; Park, K. The Hydrogel Template Method for Fabrication of Homogeneous Nano/Micro Particles J. Controlled Release 2010, 141, 314-319
24. Acharya, G.; Shin, C. S.; Vedantham, K.; McDermott, M.; Rish, T.; Hansen, K.; Fu, Y.; Park, K. A Study of Drug Release from Homogeneous PLGA Microstructures J. Controlled Release 2010, 146, 201-206
25. Streilein, J. W. Ocular Immune Privilege: The Eye Takes a Dim but Practical View of Immunity and Inflammation J. Leukoc. Biol. 2003, 74, 179-185
26. Sivak, J. M.; Ostriker, A. C.; Woolfenden, A.; Demirs, J.; Cepeda, R.; Long, D.; Anderson, K.; Jaffee, B. Pharmacologic Uncoupling of Angiogenesis and Inflammation During Initiation of Pathological Corneal Neovascularization J. Biol. Chem. 2011, 286, 44965-44975
27. Dobrovolskaia, M. A.; Mcneil, S. E. Immunological Properties of Engineered Nanomaerials Nat. Nanotechnol. 2007, 2, 469-478
28. Zolinik, B. S.; Gonzalez-Fernandez, A.; Sadrieh, N.; Dobrovolskaia, M. A. Nanoparticles and the Immune System Endocrinology 2010, 151, 458-465
29. Smith, D. M.; Simon, J. K.; Baker, J. R., Jr. Applications of Nanotechnology for Immunology Nat. Rev. Immunol. 2013, 13, 592-605
30. Barrientos, S.; Stojadinovic, O.; Golinko, M. S.; Brem, H.; Tomic-Canic, M. Growth Factors and Cytokines in Wound Healing Wound Rep. Reg. 2008, 16, 585-601
31. Qazi, Y.; Maddula, S.; Ambati, B. K. Mediators of Ocular Angiogenesis J. Genet. 2009, 88, 495-515
32. Ellenberg, D.; Azar, D. T.; Hallak, J. A.; Tobaigy, F.; Han, K. Y.; Jain, S.; Zhou, Z.; Chang, J.-H. Novel Aspects of Corneal Angiogenic and Lymphangiogenic Privilege Prog. Retinal Eye Res. 2010, 29, 208-248
33. Maddula, S.; Davis, D. K.; Maddula, S.; Burrow, M. K.; Ambati, B. K. Horizons in Therapy for Corneal Angiogenesis Ophthalmology 2011, 118, 591-599
34. Liss, R. H.; Norman, J. C. Visualization of Doxycycline in Lung Tissue and Sinus Secretions by Fluorescent Techniques Chemotherapy 1975, 21 (Suppl 1) 27-35
35. Corrales, R. M.; Villarreal, A.; Farley, W.; Stern, M. E.; Li, D.-Q.; Pflugfelder, S. C. Strain-Related Cytokine Profiles on the Murine Ocular Surface in Response to Desiccating Stress Cornea 2007, 26, 579-584
36. Shawver, L. K.; Slamon, D.; Ullrich, A. Smart Drugs: Tyrosine Kinase Inhibitors in Cancer Therapy Cancer Cell 2002, 1, 117-123
37. Ribatti, D. Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma Pharmaceuticals 2010, 3, 1225-1231
38. Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S. T. et al. Sunitinib versus Interferon alfa in Metastatic Renal Cell Carcinoma N. Engl. J. Med. 2007, 356, 115-124
39. Escudier, B.; Eisen, T.; Stadler, W. M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A. A. et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma N. Engl. J. Med. 2007, 356, 125-134
40. Gross-Goupil, M.; Francois, L.; Quivy, A.; Ravaud, A. Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma Clin. Med. Insights Oncol. 2013, 7, 269-277
41. Ando, H.; Ido, T.; Kawai, Y.; Yamamoto, T.; Kitazawa, Y. Inhibition of Corneal Epithelial Wound Healing: A Comparative Study of Mitomycin C and 5-Fluorouracil Ophthalmology 1992, 99, 1809-1814
42. Cao, R.; Lim, S.; Ji, H.; Zhang, Y.; Yang, Y.; Honek, J.; Hedlund, E.-M.; Cao, Y. Mouse Corneal Lymphangiogenesis Model Nat. Protoc. 2011, 6, 817-826
43. Yuan, X.; Mitchell, B. M.; Wilhelmus, K. R. Expression of Matrix Metalloproteinases during Experimental Candida albicans keratitis Invest. Ophthalmol. Vis. Sci. 2009, 50, 737-742